Close Menu

NEW YORK (GenomeWeb) – Akonni Biosystems announced today it has been awarded a three-year, $3 million Small Business Innovation Research grant from the National Institutes of Health.

Akonni said it will use the funding to accelerate commercialization of an assay for extensively drug-resistant tuberculosis and simultaneous drug susceptibility testing called TruArray that uses on-slide PCR within a microarray chamber. The company will also further develop the assay on its fully integrated point-of-care molecular diagnostics platform, the TruDx 3000. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.